Compare
Acadia Pharmaceuticals vs Lilly (Eli) (ACAD vs LLY)
The two stocks side by side, as of the latest close. Performance is rebased to 100 at the start of the window.
Over the past year Acadia Pharmaceuticals (ACAD) returned -4.9% and Lilly (Eli) (LLY) +46.2%; so far this year the figures are -20.5% and +26.0%.
Lilly (Eli) is the larger company by market value, about 347.1 times the size of Acadia Pharmaceuticals.
On trailing earnings, ACAD trades at 10.0 times and LLY at 43.9 times.
Revenue grew +14.8% at ACAD and +45.5% at LLY over the last year.
ACAD pays no dividend. LLY yields 0.49%.
Data as of the latest close. Not investment advice.
Relative performance
| ACAD | LLY | |
|---|---|---|
| Price | $21.23 | $1,354.00 |
| 1-day | -0.05% | -0.79% |
| YTD | -20.52% | +25.99% |
| 1 year | -4.93% | +46.25% |
| 3 years | -7.37% | +144.20% |
| Market cap | $3.7B | $1.27T |
| P/E | 10.0 | 43.9 |
| P/S | 3.05 | 14.73 |
| P/B | 2.64 | 31.63 |
| Revenue growth | +14.80% | +45.50% |
| EPS growth | +36.80% | +50.70% |
| Gross margin % | 90.5 | 83.6 |
| Net margin % | 30.1 | 31.9 |
| ROE % | 26.1 | 68.5 |
| Debt / equity | 0.00 | 1.23 |
| FCF yield % | 2.2 | 2.4 |
| Dividend yield % | — | 0.49 |
| Beta | 0.66 | 0.29 |
| RSI (14) | 52.0 | 61.1 |
| Technical rating |